Tumefactive multiple sclerosis lesions under fingolimod treatment
F Visser, MP Wattjes, PJW Pouwels, WHJP Linssen… - Neurology, 2012 - AAN Enterprises
F Visser, MP Wattjes, PJW Pouwels, WHJP Linssen, BW van Oosten
Neurology, 2012•AAN EnterprisesDiscussion. Tumefactive demyelination refers to demyelinating brain lesions mimicking
brain neoplasm clinically and radiographically. These lesions are larger than 2 cm, and
show vasogenic edema, mass effect, and variable, typical open ring enhancement after
gadolinium administration on MRI. 2 Tumefactive demyelination is a rare phenomenon. If
present, it is as the presenting demyelinating event in 61% of cases. Only 5% of tumefactive
lesions occur in established MS. 2
brain neoplasm clinically and radiographically. These lesions are larger than 2 cm, and
show vasogenic edema, mass effect, and variable, typical open ring enhancement after
gadolinium administration on MRI. 2 Tumefactive demyelination is a rare phenomenon. If
present, it is as the presenting demyelinating event in 61% of cases. Only 5% of tumefactive
lesions occur in established MS. 2
Discussion.
Tumefactive demyelination refers to demyelinating brain lesions mimicking brain neoplasm clinically and radiographically. These lesions are larger than 2 cm, and show vasogenic edema, mass effect, and variable, typical open ring enhancement after gadolinium administration on MRI. 2 Tumefactive demyelination is a rare phenomenon. If present, it is as the presenting demyelinating event in 61% of cases. Only 5% of tumefactive lesions occur in established MS. 2
American Academy of Neurology